SSCI Inc.

SSCI Inc. is a specialized firm providing comprehensive solutions in drug development, including design, optimization, and manufacturing services tailored for the pharmaceutical industry. Founded in 1991 and headquartered in West Lafayette, Indiana, US, SSCI Inc. focuses on drug development services.

In October 2006, SSCI was acquired by Aptuit, a company within the portfolio of Welsh, Carson, Anderson & Stowe and Temasek Holdings. There are no known major pivots or subsidiary relationships. SSCI Inc. specializes in a comprehensive suite of services that spans the drug development continuum.

These services include design and optimization, manufacturing, and analytical support, utilizing advanced techniques in discovery biology, medicinal chemistry, drug metabolism and pharmacokinetics (DMPK), and bioanalytical services. SSCI Inc. handles complex small molecule chemistries, including highly potent active pharmaceutical ingredients (APIs), controlled substances, and generics, addressing the evolving needs of the pharmaceutical industry. The firm's client base comprises biopharmaceutical companies worldwide, leveraging SSCI's expertise in regulatory compliance and production scalability across North America, Europe, and Asia.

SSCI Inc. generates revenue through various transactional frameworks, primarily focusing on business-to-business (B2B) partnerships with pharmaceutical and biotechnology firms. The company engages in contract manufacturing and development agreements, where clients typically compensate SSCI for services rendered in the form of project-based contracts or retainer fees. These transactions often involve the development of customized solutions for drug discovery and production, including key services such as API manufacturing, formulation development, and analytical testing.

SSCI's revenue model is supported by strategic collaborations and partnerships that facilitate long-term engagements with clients, ensuring a continuous flow of business as these companies advance their product pipelines. The firm's flagship offerings include proprietary services in flow chemistry and sterile API manufacturing, integral to modern drug development. As of October 2006, SSCI Inc. has been part of Aptuit, focusing on expanding its market reach and service offerings.

While specific details regarding upcoming product launches or geographic expansions were not provided, the company aims to enhance its offerings in drug development services. The acquisition by Aptuit is anticipated to bolster SSCI's capacity to innovate and grow within the pharmaceutical sector.